A Vancouver-based RNA medicines company has emerged from stealth with $150 million in financing from investors Versant Ventures and Novartis. Many forms of prevalent kidney disease remain unaddressed, and this is the area where Borealis Biosciences operates. Borealis was founded on the premise that a convergence of scientific and translational breakthroughs can enable RNA therapeutics […]